HDAC9 and ovarian carcinoma: In vitro experiments demonstrated that pretreating ovarian cancer cells with valproic acid (an HDAC inhibitor) resulted in an elevated expression of NKG2D ligands, consequently enhancing the efficacy of NKG2D-CAR-T cell therapy (15).